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Abstract 
MicroRNAs (microRNAs or miRs) are small, non-
coding RNAs that control gene expression by binding to 
and repressing specific mRNA target and have emered 
as powerful regulators of many biological processes. 
Understanding miRNAs-biology and functions may be 
pivotal to get a better insight into pathophysiological 
mechanisms responsible for a large number of morbid 
conditions and may lay the foundations for the 
development of novel therapeutic interventions. 
Moreover, besides their intracellular functions, miRs are 
present in the human circulation in a remarkably stable 
cell-free form, and their plasmatic levels have been 
proposed as biomarkers for several pathological 
conditions. The present review aims to summarize the 
current evidences with regard to biological role of 
miRNAs in cardiovascular system and their 
involvement in the pathogenesis of cardiovascular 
diseases including atherosclerosis, heart failure and 
pathological heart and vascular remodelling and to 
highlight their potential use as novel biomarkers and as 
therapeutic targets in cardiac and vascular diseases. 
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Protein-coding genes represent only 1.1% of the 
human genome[1]. However, more than 70% of the 
human genome is transcribed giving rise to non-coding 
ribonucleic acids (RNAs), which are not converted into 
proteins but play important roles in regulation of 
pathophysiological processes and tissue homeostasis. 
Several classes of non-coding RNAs have been 
recognized, including microRNAs (miRNAs or miRs), 
long non-coding RNAs (lncRNAs) and circular RNAs 
(circRNAs). MicroRNAs are short (17 to 25 
nucleotides), lncRNAs are composed by longer (>200 
nucleotides) sequences, whereas circRNAs are 
generated by back-splicing reactions[2]. Among these 
latters, microRNAs are currently the subcategory of 
non-coding RNAs with the largest amount of evidences, 
in both experimental and clinical setting. Indeed, since 
their discovery in 1993 in Caenorhabditis elegans[3], 
miRNAs have emerged as key modulators of complex 
biological processes, including those involved in many 
cardiovascular diseases[4, 5]; overall, it has been 
estimated that between 30 and 50% of all coding genes 
are regulated by miRNAs. Moreover, it has been 
demonstrated that miRNAs are present in the human 
circulation in a remarkably cell-free form and that their 
plasmatic levels are differently regulated in many 
pathological conditions, thus opening attractive 
possibilities for use of circulating miRs as disease 
biomarkers[6]. Lastly, the concept of miR-based 
therapies is currently developing; the first miR-targeted 
drug has been developed in 2008 for treatment of 
hepatitis C and is currently tested in a phase 2b clinical 
trial; in cardiovascular field, promising perspectives are 
arising from preclinical studies involving a wide range 
of cardiovascular disorders, although several concerns 
remain to be overcome. Aim of the present review is to 
provide an overview of microRNAs-biology and of the 
most relevant experimental evidence underlying their 
involvement in cardiovascular diseases, summarize the 
current evidence of their potential role as novel disease 
biomarkers and discuss potentialities and limitations of 
miR-therapeutics in different cardiac and vascular 
pathologic conditions.   
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Biology of microRNAs 
The transcription of the primary miRNA (pri-
miRNA) from the genome is mediated by the nuclear 
RNA polymerase II[7]. The pri-miRNA is processed 
into a precursor miRNA (pre-miRNA), composed from 
60-70 nucleotides, by the enzyme complex of Drosha-
Dgcr8; the pre-miRNA is thereafter transported to the 
cytoplasm by the GTP-dependent nuclear export factor 
Exportin-5 and here it is cleaved by the RNAse III 
enzyme complex into the mature duplex miRNA. Of 
this latter, one strand (the mature microRNA) is 
incorporated into the miRNA-induced silencing 
complex (miRISC), while the other strand (passenger 
strand) is usually degraded. More recently, non-
canonical pathways for miRNA-biogenesis, 
alternatively including Drosha- or Dicer-independent 
mechanisms, have emerged[8]. The main biological 
function of miRNAs is to regulate gene expression at 
the post-transcriptional level, by binding to specific 
mRNAs; depending on the degree of complementarity, 
a specific miRNA may either induce the degradation of 
the target mRNA or, most frequently, prevent its 
translation into proteins[7]. The regulatory function of 
miRNAs is powerful and fine-regulated. Indeed, 
because of the partial complementarity, a single miR 
can modulate the expression of several genes; 
moreover, miRs with partial overlapping of their 
binding sites can target the same gene-translate and can 
interact each other to form miRs-clusters, thus making 
their regulatory potential even larger. 
 
MicroRNAs and cardiovascular system. 
The crucial role of miRNAs in the cardiovascular 
system is supported by the finding that depletion of 
miRNAs-processing enzyme Dicer leads to defects in 
angiogenesis, vessel formation and cardiac 
development. Specific miRs are differently expressed in 
various cells and tissues composing the cardiovascular 
system. In detail, several miRs are expressed in 
endothelial cells (ECs), where they act as regulators 
(activators- like miR-27b, miR-130a, miR-126, or 
inhibitors- like miR-221 and miR-222) of angiogenesis 
and vasculogenesis[9, 10]; other miRs are expressed in 
vascular smooth muscle cells (VSMCs) and regulate 
their differentiation and contractile function[11, 12]; 
further, other miRs (like miR-1 and miR-208) are 
preferentially expressed in cardiomyocytes and are 
involved in physiological cardiac development as well 
as in pathological myocardial hypertrophy[13-15]. In 
the present review, we focused on miRs that have been 
demonstrated to be involved in common pathological 
cardiovascular conditions as atherosclerosis, vascular 
remodelling, coronary artery disease and heart failure. 
 
MicroRNAs and atherosclerosis. 
Atherosclerosis is a multifactorial, chronic disease 
whose pathophysiological mechanisms remained 
currently only partially understood. Pivotal processes in 
initiation and development of atherosclerosis included 
endothelial cells dysfunction, infiltration of vascular 
intima by inflammatory cells, lipid accumulation and 
vascular smooth muscle cells (VSMCs) dysregulation. 
In detail, endothelial dysfunction is thought to represent 
the initiating step in the development of an 
atherosclerotic plaque: following various potential form 
of injuries (i.e., increased vascular wall shear stress, 
pressure overload, increased levels of LDL or free 
radicals, diabetes and so on), EC function is impaired 
leading to increases endothelial permeability and up-
regulation of leucocyte and endothelial adhesion 
molecules. Then, circulating leucocytes adhere to 
activated endothelium and migrate into the artery wall; 
in particular, T-lymphocytes and lipid-laden 
macrophages (foam cells) accumulate in the vascular 
wall and release proteases, cytokines, chemokynes and 
growth factors that perpetuate the inflammation process. 
In addition, vascular smooth muscle cells (VSMCs) 
migrate and proliferate within the developing plaque 
and undergo relevant phenotypic changes, switching 
form a synthetic to a proliferative state that has a pivotal 
role in the further expansion of the atherosclerotic 
lesion.  
Specific miRNAs have been shown to play a key 
role in the modulation of various important processes 
linked to vascular and endothelial cell biology[5]. In 
cultured ECs, several specific miRs have been shown to 
stimulate or inhibit angiogenesis[16]. Importantly, 
miRNAs have indeed been shown to be involved in 
most of the steps necessary for the development of an 
atherosclerotic plaque. MiR-126 is one of the first miR 
to be identified as involved in the development of 
atherosclerosis. MiR-126 is highly expressed in EC and 
its expression is essential for vascular development[17]. 
Experimental studies have shown that mir-126 is key in 
maintaining a proliferative reserve of ECs in response to 
shear stress and that reduced levels of this miR reduced 
ECs proliferation, promoting plaque formation[18, 19]. 
Furthermore, miR-126 has been shown to inhibit the 
expression of vascular cell adhesion molecule-1 
(VCAM-1), thus preventing leucocyte adherence to 
ECs[20]. On the contrary, miR-21 has been 
demonstrated to increase neointima formation and ECs-
apoptosis, thus favouring atherosclerotic process. With 
regard to inflammation, expression of miR-155 has been 
shown to be induced by cytokines like TNF-α and IFN-
β and such increased expression contributes to 
physiological expansion of granulocyte and monocyte 
populations during inflammation. MiR-155 is 
ubiquitously expressed and, in the context of an 
atherosclerotic lesion, it has been shown to modulate 
different biological processes in ECs, in foam cells and 
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in VSMCs. On the contrary, miR-143 and miR-145 are 
preferentially expressed in VSMCs, where they act as 
regulator of their differentiation. Recently, the muscle-
enriched miR-133, initially identified in cardiac and 
skeletal muscle, has been demonstrated to be also 
expressed in VSMCs, where it regulates their 
“phenotypic switch” (from a contractile to a synthetic 
status) in response to vascular injury[21]. 
Coronary artery disease.  
Specific microRNAs and microRNAs-cluster have 
been shown to be modulated in the setting of both stable 
and unstable coronary artery disease. Circulating levels 
of microRNAs that are highly expressed in the 
myocardium (miR-1, miR-133, miR-208 and miR-499) 
are significantly increased in patients with ACS, and 
have been shown to be directly correlated with extent of 
myocardial damage and with patients’ prognose[22-24]. 
Therefore, these miRs have been proposed as novel 
tools to improve specificity and sensitivity of 
established markers of myocardial injury like high-
sensitivity Troponin T (hs-Trop T) in the diagnosis of 
ACS. In particular, specific muscle-enriched miRs have 
been shown to be released very early during ACS, 
within 30 minutes from symptoms onset[22], and could 
therefore be useful in the diagnosis of ACS patients 
presenting early, at a time where hs-Troponin T is still 
negative. Moreover, detection of specific miRs linked 
with myocardial ischaemia could be useful in the 
differential diagnosis among several pathological 
conditions potentially associated with elevation of 
traditional cardiac biomarkers[25, 26]. Beyond the acute 
setting, several studies suggested that a number of 
microRNAs may be useful novel biomarkers in the 
diagnosis and prognosis of patients suffering from 
stable CAD. In detail, microRNAs highly expressed in 
endothelial cells (miR-126, miR17, miR92a) have been 
found to be significantly downregulated in patients with 
CAD compared with healthy controls. Moreover, three 
microRNAs (miR-126, miR-197 and miR-223) were 
able to predict subsequent AMI in the general 
population at 10-years follow-up[27]. Interestingly, 
changes in the kinetics of miR-concentrations through 
the transcoronary circulation have been linked with 
overall coronary plaque burden and morphological 
plaque characteristics in patients with stable CAD. In 
details, transcoronary concentration gradients of the 
anti-atherosclerotic miR-126 and miR-145 were 
associated with extent of coronary vulnerable plaques, 
suggesting that the local uptake or degradation of 
specific miRs may be linked with instable plaque 
phenotype[28]. 
 
Pathological vascular remodelling. 
Pathological vascular remodelling is a widely used 
term to indicate a great number of dynamic processes 
leading to active structural changes in the vessel wall 
structure[29] in response to vascular injury. VSMCs and 
extracellular matrix (ECM) proteins are principally 
involved in this process. It is well known that VSMCs, 
unlike adult skeletal and cardiac muscle cells, retain a 
remarkable phenotypic plasticity and can undergo 
relevant changes in gene expression, contractile 
function, cell cycle state and production of ECM and 
inflammatory proteins, which represent one of the first 
steps in the development of an atherosclerotic 
lesion[30]. Recently, miR-133a has been shown to be 
involved in the “phenotypic switch” of VSMCs from a 
contractile to a proliferative state, suggesting that this 
miR could indeed play an important role in the 
development of pathological vascular remodelling and 
in vasculoproliferative diseases[21]. Moreover, 
increased cardiac release of this miR has been recently 
associated with higher incidence of restenosis after 
coronary stent-implantation[24]. Another miR that was 
associated with vascular remodelling is miR-29b. This 
miR was first described as a stress-induced miR in the 
heart and has emerged as novel key regulator of 
vascular homeostasis, moderating the expression levels 
of multiple gene transcripts encoding various 
components of extracellular matrix (ECM), like type I 
and type III collagen, fibrillin-1 and elastin[31]. All 
miR-29-family members act as endogenous inhibitors of 
ECM proteins expression and, consistently, their 
downregulation in vivo induces a fibrotic response in 
various organs, including heart[31], liver[32], 
kidney[33] and skin[34]. Similarly, in the vasculature 
miR-29 targets play a pivotal role in maintaining the 
integrity of the vessel wall. In this setting, it has been 
shown that miR-29b plays a pivotal role in the 
formation of aortic aneurysms and that its inhibition 
reduces aneurysm formation in different murine 
models[35, 36]. In the atherosclerotic coronary tree, 
miR-29b levels have been found to be reduced in 
patients with larger extent of fibrotic coronary plaques 
consistently with experimental studies demonstrating 
that a reduction of miR-29b may lead to an up-
regulation of ECM proteins and, therefore, increase 
tissue fibrosis[28]. Lastly, miR-34 has been associated 
with age-related vessel degeneration; this miR is 
upregulated in senescent endothelial cells and VSMCs, 
where it targets pivotal cell cycle regulators (including 
SIRT1 and Bcl-2) promoting cellular death[37]. 
 
MicroRNAs, pathological cardiac remodelling 
and heart failure. 
Alterations in microRNAs-biogenesis pathways 
have been demonstrated to be linked with biventricular 
dilatation and fibrosis, myocyte hypertrophy, foetal 
gene reprogramming and sudden death, implicating a 
pivotal role of miRNAs in cardiac remodelling and 
development of heart failure (HF). Cardiomyocyte-
enriched miRNAs miR-1 and miR-133 have been 
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extensively studied in this pathological setting. In detail, 
expression of both miRs has been found to be inversely 
associated with cardiac hypertrophy in animal and 
human specimens[13], and forced expression of miR-1 
was able to revert cardiac hypertrophy in an animal 
model[38]. In contrast, reduced expression of cardiac-
specific miR-208 has been linked with improvement of 
cardiac function and increased survival in a rat model of 
HF[38]. Interestingly, specific miRs have been shown 
to be involved in alterations of specific regulatory 
pathways in different pathogenetic and clinical settings 
of HF. For instance, experimental overexpression of 
miR-24 in ischemic myocardium has been associated 
with reduced infarct size, improved cardiac function and 
prevention of HF[39]. On the contrary, increased 
expression of miR-34 has been associated with 
pathological left ventricular remodelling after acute 
myocardial infarction[40], as well as with HF of non-
ischemic aetiology[41]; indeed, experimental studies 
have demonstrated that miR-34 is induced in the ageing 
heart and that in vivo silencing or genetic deletion of 
this miR reduces age-associated cardiomyocyte cell 
death, contributing to the age-dependent decline in 
cardiac function. Mechanistically, identified miR-34 
target PNUTS and Foxo3a are known to play a pivotal 
role in the modulation of apoptosis and myocardial cell 
loss, contributing to chronic myocardial damage both in 
ischaemic and non-ischaemic HF[37, 42, 43]. 
Modulation of endothelial-enriched miR-126 has also 
been reported in patients with HF, where they are 
correlated with age, LV-function, NT-proBNP levels 
and atrial volume[44]. Moreover, reduced miR-126 
levels in circulating endothelial progenitor cells (EPCs) 
result in reduced cardiac repair potential, impaired 
EPCs-mobilization and homing in response to 
myocardial hypoxia and impaired angiogenesis and it is 
associated with poor patients’ prognosis[45, 46]. 
 
Potential therapeutic applications 
Given their key role in the regulation of a great 
number of biological processes involved in the disease 
pathogenesis, miRNAs-modulation represents a 
promising novel therapeutic strategy. Therapeutic 
application of miRs include the use of either inhibitors 
of miRs (antagomiRs, also named anti-miRs or 
blockmiRs) or overexpression of miRs by using adeno-
associated viruses[47]. Currently, use of anti-miRs is 
preferred over that of adenovirus because of a better 
safety profile. AntimiRs are chemically engineered 
oligonucleotides developed in order to prevent the 
miRs-modulated posttrascriptional gene regulation[48]. 
AntagomiRs have a sequence that is complementary to 
a mRNA-sequence that serves as a binding site for 
microRNA; upon binding, antagomiRs sterically inhibit 
miRs from binding at the same site, and so prevent the 
miRs-induced degradation of target mRNA. The first 
microRNA-targeted drug (Miravirsen) has been 
developed in 2008 for the therapy of Hepatitis C virus 
(HCV) infection to prevent miR-122-mediated stability 
and propagation of HCV-RNA. The results of the phase 
2a clinical trial of miravirsen reported a dose-dependent 
reduction of HCV-RNA levels after five weekly 
injection, that lasted up to 10 weeks after the active 
treatment phase, moreover showing an excellent safety 
profile[49]. In the cardiovascular field, antagomiRs 
against miR-33a and miR-33b (miRs involved in the 
regulation of cholesterol transport) led to sustained 
elevation of plasmatic high-density lipoprotein (HDL) 
cholesterol and reduction in very-low-density 
lipoprotein (VLDL) cholesterol without any adverse 
side effects in non-human primates[50]. Along the same 
line, antagomiRs against microRNA-29b have been 
developed and are currently tested in animals for the 
healing of aortic aneurysms[51]. Despite these 
encouraging premises, several concerns regarding the 
potential therapeutic use of miRs-modulators in 
cardiovascular system have been taken into account. In 
particular, it has to been underlined that the most miRs 
identified as potential therapeutic targets in 
cardiovascular diseases are ubiquitously expressed, 
raising concerns with regard to both efficiency of the 
therapy and “off-targets” systemic effects. Indeed, 
targeting the cardiovascular system would require 
higher anti-miRs doses compared with those required 
when antimiRs are directly delivered into the target 
organ, and adverse effects could occurr (i.e., 
nephrotoxicity). Moreover, monitoring of successful 
target engagement appears to be difficult in a systemic 
setting. Thus, strategies allowing local or cell-specific 
delivery of miRs and systems to monitor on-target 
effects could be required before miRNA-manipulations 
could become a reliable and feasible therapeutic 
intervention in the clinical practice. 
 
Conclusions. 
Continuously growing evidence shows that 
microRNAs play an active and pivotal role in many 
biological processes involved in the pathogenesis of 
several widespread cardiovascular diseases. Data 
deriving from clinical and experimental studies open 
attractive possibilities for use of microRNAs as 
diagnostic and prognostic biomarkers in the clinical 
practice and could lay the foundation for development 
of microRNAs-based therapeutic interventions. 
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